Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Intrauterine Drug Delivery Systems

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

Transdermal Drug Delivery Systems

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...

Hormonal Regulation of the Menstrual Cycle

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Hormonal Control of the Ovarian Cycle

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...

Birth Control Methods

Birth Control Methods

Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although vasectomy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use.

Climacteric : the journal of the International Menopause Society·2017

Same author

Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.

Climacteric : the journal of the International Menopause Society·2017

Same author

[Asphyxiating thoracic dysplasia (Jeune syndrome): about two cases].

Journal de gynecologie, obstetrique et biologie de la reproduction·2009

Same author

Small cell carcinoma of the ovary successfully treated with radiotherapy only after surgery: case report.

European journal of gynaecological oncology·2008

Same author

The long-term tolerability and efficacy of OESCLIM: results of a 1-year study.

Maturitas·2000

Same author

The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group.

Clinical endocrinology·1993

Search research articles

Related Experiment Video

Updated: May 9, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.

¹Obstetrics and Gynecology Department, Centre Hospitalo-Universitaire Brugmann, Université Libre de Bruxelles, Bruxelles, Belgium.

Climacteric : the Journal of the International Menopause Society

|July 16, 2013

Summary

This summary is machine-generated.

Optimized hormone replacement therapy (HRT) uses transdermal estrogen and natural progesterone to safely manage menopausal symptoms and reduce risks. This approach offers cardioprotection and endometrial safety, making it ideal for long-term use in healthy women.

More Related Videos

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

Published on: June 7, 2012

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Related Experiment Videos

Last Updated: May 9, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration

Published on: June 7, 2012

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Area of Science:

Endocrinology
Gynecology
Cardiology

Background:

Hormone replacement therapy (HRT) is a primary treatment for menopausal symptoms.
Estrogen may offer cardioprotection, but progestogens, especially medroxyprogesterone acetate (MPA), can interfere.
Oral HRT carries risks like venous thromboembolism (VTE), gallbladder disease, and stroke.

Purpose of the Study:

To evaluate an optimized HRT regimen for menopausal symptom management.
To assess the safety and efficacy of transdermal estradiol and micronized natural progesterone.
To compare risks associated with different HRT formulations and administration routes.

Main Methods:

Review of existing literature on HRT formulations and their effects.
Analysis of cardiovascular, thromboembolic, and oncologic outcomes associated with various HRT components.
Comparison of transdermal versus oral estrogen delivery and synthetic versus natural progestogens.

Main Results:

Transdermal estradiol prevents risks associated with oral HRT, including VTE, stroke, and gallbladder disease.
Transdermal HRT is advantageous for women with cardiovascular risk factors, diabetes, hypertension, and older age.
Continuous combined estrogen and natural progesterone provides optimal endometrial protection and cardiovascular benefits.
Natural progesterone, unlike MPA, has a favorable cardiovascular profile and does not appear mitogenic on breast cells.

Conclusions:

Optimized HRT, combining low-dose transdermal estrogen with oral micronized natural progesterone, is safe and effective for long-term menopausal symptom management.
This regimen minimizes risks of VTE, stroke, and breast cancer, offering cardioprotection.
Asymptomatic women at risk for fractures can also benefit from optimized HRT if the risk-benefit ratio is favorable.